Arvind Remedies Ltd Stock Analysis

BSE: 531823 | NSE: ARVINDREM | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Arvind Remedies

M-Cap below 100cr DeciZen not available


1. Is Arvind Remedies Ltd. a good quality company?

Data is not available for this company.

2. Is Arvind Remedies Ltd. undervalued or overvalued?

No data found

3. Is Arvind Remedies Ltd. a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Arvind Remedies Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Arvind Remedies:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide
ROCE % 7.5%8.1%8.1%8.8%11.1%10.9%9.6%13.4%14%-34.6%-

Growth Parameters

Growth Parameters Colour Code Guide
Sales 14415717621829836343766491163012
YoY Gr. Rt. %-8.8%12.2%24%36.7%21.8%20.4%52.1%37.2%-30.9%-
Adj EPS 1.31.721.74.13.548.48.6-38.6-20.2
YoY Gr. Rt. %-34.4%17.9%-15.7%144.3%-14.2%14.9%109%2.9%-546.3%-
BVPS (₹) 14.815.917.218.52225.228.135.439.9-5.8-23.6
Adj Net Profit
Cash Flow from Ops. -8.610.116-13-7.712.1713.3-60.3-121-
Debt/CF from Ops. -


CAGR Colour Code Guide
9 Years 5 Years 3 Years 1 Years
Sales 17.8%16.2%13%-30.9%
Adj EPS -246.4%-256.7%-312.5%-546.3%
BVPS -190.2-176.7-159.2-114.6
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide
Return on Equity % 8.711129.414.915.614.62424.9-277136.9
Op. Profit Mgn %
Net Profit Mgn %
Debt to Equity
Working Cap Days 1741831821921862252292112252700
Cash Conv. Cycle 1251381221231181241451311302120

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Arvind Remedies Ltd.

Standalone Consolidated
TTM EPS (₹) -20.2 8.6
TTM Sales (₹ Cr.) 12.2 963
BVPS (₹.) -23.6 0
Reserves (₹ Cr.) -229 208
P/BV -0.20 0.00
PE 0.00 0.55
From the Market
52 Week Low / High (₹) 4.70 / 4.70
All Time Low / High (₹) 3.78 / 110.00
Market Cap (₹ Cr.) 32
Equity (₹ Cr.) 68.1
Face Value (₹) 10
Industry PE 38.3

Management X-Ray of Arvind Remedies :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.0030.4536.8928.8655.7799.5999.5999.5999.5999.59
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes


About Arvind Remedies Ltd

Arvind Remedies forayed into the world of quality healthcare in 1988 under the dynamic and ambitious stewardship of Arvind Shah, Managing Director and Chief Executive Officer.

The company was incorporated as a private limited company and started manufacturing and marketing of world-class allopathic and ayurvedic pharmaceutical products within and outside India, thus beginning to realise the vision of bringing high quality healthcare to the common man. Having grown notably in terms of production capacity, product categories, market share, advancements in R&D, market reach and global acceptance, the company is today a significant force to reckon with in the Indian pharmaceutical industry.

The company entered the field at a time when the Indian pharmaceutical industry was itself at the threshold of a new era, where product patenting and holistic healthcare were gaining prominence. The company’s core strength aptly lay in the ability to deliver both Western and Eastern varieties of quality treatments. Significant contributions have been made to the fields of cardiology, dermatology, nephrology and diabetes, among others. Having established its credibility as a company committed to providing world-class healthcare products, Arvind Remedies went public in April 1996 getting listed on the Bombay, Ahmedabad and Chennai Stock Exchanges. The public issue comprised of 30 lakh equity shares of Rs 10 each, at a premium of Rs 20 per share.

The company has also won international acceptance and recognition with exports to Africa, Commonwealth of Independent States and Asian countries.

Spread across 40,000 sq ft of own land, on which the built area is 30,000 sq ft, Arvind Remedies’ infrastructure and facilities are among the best and most modern in the world. ARL's state-of-the-art manufacturing facility and sophisticated research & development lab, located in the SIDCO Industrial area at Kakkalur, 45 km from Chennai, has been certified with GMP, under WHO norms. This factory manufactures pharmaceutical products in various dosages, like tablets, capsules, liquids, ointments, creams, suspensions, dry syrups, in addition to ayurvedic and herbal products.

Arvind Remedies has a sophisticated R&D lab well-equipped with instruments like HPLC, FTIR, UV Spectro Photo Meter, Dissolution Apparatus, Auto Titrator, Metler Balances, Digital DT Machine, etc. Focus areas are development of drug delivery systems, new formulations, process development of various dosage forms.


1. Allopathic

• Ethical Products  • Branded Generic Products • Generic Products

2. Ayurvedic

• Artin oil • Hygenex • Pankare • Pankare (Tab.) • Solufat • Sorexil • Stresof • Utritone


• Defence establishments • ESI • CGHS • Central and state government institutions • Public sector companies • P&T • Railways, and • World Bank Projects.

Awards/ Recognition

  • 2010
    Arvind Remedies Ltd - Kakkalur, Thiruvallore manufacturing unit has been awarded Tamil Nadu Govt State Safety Award for the year 2010 from the Industrial Safety & Health, Tamil Nadu.
  • 2011-12
    Arvind Remedies Ltd has been awarded pioneers Award for Excellence in Healthcare 2012 from the Ministry of Health & Family Welfare in association with FICCI.
    Excellence Award received by Dr. B. Arvind Shah, MD and CEO from His Excellency the Governor of Tamil Nadu, V. Rosaiah for his contribution to the pharmaceutical industry for the year 2011-12.
Read More Read Less